BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Sanofi to present new data from 14 abstracts across multiple sclerosis at ECTRIMS 2025 congress in Barcelona, Spain ...

Pipeline Insight, 2025 ” explores a dynamic portfolio of emerging therapies poised to redefine management. Next-generation ...

GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.

Dubai: The Emirates Medicines Establishment has launched its Contact Center at 80033784 (800Edrug), which will serve as a ...

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up? Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate ...

Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

EDE plays a pivotal role in realising the UAE’s vision for leadership and sustainability. It will continue to develop ...

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety ...

Micah Parsons said he's been dealing with with a sprained L4-L5 facet joint in his spine. The cure seems to have been a change of scenery and a new contract, ...

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​Enrollment for registrational Phase ...